A pilot study of interleukin-2 for adult patients with acute myelogenous leukemia in first complete remission

Cancer

Volumn 85, Issue 7, 1999, Pages 1506-1513

  Cortes, Jorge E ^a   Kantarjian, Hagop M ^a   O'Brien, Susan ^a   Giles, Francis ^a   Keating, Michael J ^a   Freireich, Emil J ^a   Estey, Elihu H ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Acute myeloid leukemia; Antecedent hematologic disorder; Interleukin 2; Maintenance

Indexed keywords

INTERLEUKIN 2;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CHROMOSOME 11; CHROMOSOME ABERRATION; CHROMOSOME ANALYSIS; CLINICAL ARTICLE; CONTROLLED STUDY; HEMATOLOGIC DISEASE; HUMAN; KARYOTYPE; LEUKEMIA REMISSION; PRIORITY JOURNAL; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; CHROMOSOME ABERRATIONS; DRUG ADMINISTRATION SCHEDULE; HUMANS; INTERLEUKIN-2; LEUKEMIA, MYELOCYTIC, ACUTE; MIDDLE AGED; PILOT PROJECTS; REMISSION INDUCTION; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 0033120418     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19990401)85:7<1506::AID-CNCR11>3.0.CO;2-O     Document Type: Article

References (42)

1. Cole N, Gibson BE. High-dose cytosine arabinoside in the treatment of acute myeloid leukaemia. Blood Rev 1997;11(1): 39-45.
2. Buchner T. Treatment of adult acute leukemia. Curr Opin Oncol 1997;9(1):18-25.
3. Ferrant A, Labopin M, Frassoin F, Prentice HG, Cahn JY, Biaise D, et al. Karyotype in acute myeloblastic leukemia: prognostic significance for bone marrow transplantation in first remission: a European Group for Blood and Marrow Transplantation Study. Blood 1997;90(8):2931-8.
4. Harousseau J-L, Cahn J-Y, Pignon B, Witz F, Milpied N, Delain M, et al. Comparison of autologous bone marrow transplantation and intensive chemotherapy as postremission therapy in adult acute myeloid leukemia. Blood 1997; 90(8):2978-86.
5. Mayer RJ, Davis RB, Schiffer CA, Berg DT, Powell BL, Schulman P, et al. Intensive postremission chemotherapy in adults with acute myeloid leukemia. N Engl J Med 1994; 331(14):896-903.
6. Keating MJ, Kantarjian H, Smith TL, Estey E, Walters R, Andersson B, et al. Response to salvage therapy and survival after relapse in acute myelogenous leukemia. J Clin Oncol 1989;7(8):1071-80.
7. Horowitz MM, Gale RP, Sondel PM, Goldman JM, Kersey J, Kolb HJ, et al. Graft-versus-leukemia reactions after bone marrow transplantation. Blood 1990;75(3):555-62.
8. Weiden PL, Sullivan KM, Flournoy N, Storb R, Thomas ED. Antileukemic effect of chronic graft-versus-host disease: contribution to improved survival after allogeneic marrow transplantation. N Engl J Med 1981;304(25):1529-33.
9. Foa R, Fierro MT, Cesano A, Guarini A, Bonferroni M, Raspadori D, et al. Defective lymphokine-activated killer cell generation and activity in acute leukemia patients with active disease. Blood 1991;78(4):1041-6.
10. Henney CS, Kuribayashi K, Kern DE, Gillis S. Interleukin-2 augments natural killer cell activity. Nature 1981;291(5813): 335-8.
11. Oshimi K, Oshimi Y, Akutsu M, Takei Y, Saito H, Okada M, et al. Cytotoxicity of interleukin 2-activated lymphocytes for leukemia and lymphoma cells. Blood 1986;68(4):938-48.
12. Fierro MT, Liao XS, Lusso P, Bonferroni M, Matera L, Cesano A, et al. In vitro and in vivo susceptibility of human leukemic cells to lymphokine activated killer activity. Leukemia 1988; 2(1):50-4.
13. Thompson JA, Peace DJ, Klarnet JP, Kern DE, Greenberg PD, Cheever MA. Eradication of disseminated murine leukemia by treatment with high-dose interleukin 2. J Immunol 1986; 137(11):3675-80.
14. Johnson CS, Thurlow SM, Furmanski P. Lymphokine-activated killer cell plus recombinant interleukin-2 therapy of erythroleukemia in mice. Leukemia 1989;3(2):91-6.
15. Foa R, Meloni G, Tosti S, Novarino A, Fenu S, Gavosto F, et al. Treatment of acute myeloid leukaemia patients with recombinant interleukin 2: a pilot study. Br J Haematol 1991;77(4):491-6.
16. Meloni G, Foa R, Vignetti M, Guarini A, Fenu S, Tosti S, et al. Interleukin-2 may induce prolonged remissions in advanced acute myelogenous leukemia. Blood 1994;84(7):2158-63.
17. Meloni G, Vignetti M, Andrizzi C, Capria S, Foa R, Mandelli F. Interleukin-2 for the treatment of advanced acute myelogenous leukemia patients with limited disease: updated experience with 20 cases. Leukemia Lymphoma 1996;21(5-6):429-35.
18. Bergmann L, Heil G, Kolbe K, Lengfelder E, Puzicha E, Martin H, et al. Interleukin-2 bolus infusion as late consolidation therapy in 2nd remission of acute myeloblastic leukemia. Leukemia Lymphoma 1995;16(3-4):271-9.
19. Lim SH, Newland AC, Kelsey S, Bell A, Offerman E, Rist C, et al. Continuous intravenous infusion of high-dose recombinant interleukin-2 for acute myeloid leukaemia-a phase II study. Cancer Immunol Immunother 1992;34(5): 337-42.
20. Soiffer RJ, Murray C, Cochran K, Cameron C, Wang E, Schow PW, et al. Clinical and immunologic effects of prolonged infusion of low-dose recombinant interleukin-2 after autologous and T-cell-depleted allogeneic bone marrow transplantation. Blood 1992;79(2):517-26.
21. Soiffer RJ, Murray C, Gonin R, Ritz J. Effect of low-dose interleukin-2 on disease relapse after T-cell-depleted allogeneic bone marrow transplantation. Blood 1994;84(3):964-71.
22. Klingemann HG, Phillips GL. Is there a place for immunotherapy with interleukin-2 to prevent relapse after autologous stem cell transplantation for acute leukemia? Leukemia Lymphoma 1995;16(5-6):397-405.
23. Macdonald D, Jiang YZ, Gordon AA, Mahendra P, Oskam R, Palmer PA, et al. Recombinant interleukin 2 for acute myeloid leukaemia in first complete remission: a pilot study. Leukemia Res 1990;14(11-12):967-73.
24. Cheson BD, Cassileth PA, Head DR, Schiffer CA, Bennett JM, Bloomfield CD, et al. Report of the National Cancer Institute-sponsored workshop on definitions of diagnosis and response in acute myeloid leukemia. J Clin Oncol 1990;8(5): 813-9.
25. Ghaddar HM, Pierce S, Kantarjian HM, Freireich EJ, Keating MJ, Estey EH. Amsacrine and continuous-infusion highdose cytosine arabinoside as induction therapy for patients with newly-diagnosed acute myelogenous leukemia. Leukemia Lymphoma 1996;22(1-2):71-6.
26. Kaplan ES, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-81.
27. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 1966;50:163-70.
28. de Lima M, Strom SS, Keating M, Kantarjian H, Pierce S, O'Brien S, et al. Implications of potential cure in acute myelogenous leukemia: development of subsequent cancer and return to work. Blood 1997;90(12):4719-24.
29. Estey E, Thall PF, Kantarjian H, O'Brien S, Koller CA, Beran M, et al. Treatment of newly diagnosed acute myelogenous leukemia with granulocyte-macrophage colony-stimulating factor (GM-CSF) before and during continuous-infusion high-dose ara-C + daunorubicin: comparison to patients treated without GM-CSF. Blood 1992;79(9):2246-55.
30. Messina C, Zambello R, Rossetti F, Gazzola MV, Varotto S, Destro R, et al. Interleukin-2 before and/or after autologous bone marrow transplantation for pediatric acute leukemia patients. Bone Marrow Transp 1996;17(5):729-35.
31. Robinson N, Sanders JE, Benyunes MC, Beach K, Lindgren C, Thompson JA, et al. Phase 1 trial of interleukin-2 after unmodified HLA-matched sibling bone marrow transplantation for children with acute leukemia. Blood 1996;87(4): 1249-54.
32. Massumoto C, Benyunes MC, Sale G, Beauchamp M, York A, Thompson JA, et al. Close simulation of acute graft-versus-host disease by interleukin-2 administered after autologous bone marrow transplantation for hematologic malignancy. Bone Marrow Transp 1996;17(3):351-6.
33. Benyunes MC, Massumoto C, York A, Higuchi CM, Buckner CD, Thompson JA, et al. Interleukin-2 with or without lymphokine-activated killer cells as consolidative immunotherapy after autologous bone marrow transplantation for acute myelogenous leukemia. Bone Marrow Transp 1993;12(2): 159-63.
34. Biaise D, Attal M, Pico JL, Reiffers J, Stoppa AM, Bellanger C, et al. The use of a sequential high dose recombinant interleukin 2 regimen after autologous bone marrow transplantation does not improve the disease free survival of patients with acute leukemia transplanted in first complete remission. Leukemia Lymphoma 1997;25(5-6):469-78.
35. Maraninchi D, Biaise D, Viens P, Brandely M, Olive D, Lopez M, et al. High-dose recombinant interleukin-2 and acute myeloid leukemias in relapse. Blood 1991;78(9):2182-7.
36. Shepherd JD, Jacky E, Gratwohl A, Helbig W, Maraninchi D, Zittoun R, et al. Phase II study of subcutaneous rHu interleukin-2 in patients with acute myelogenous leukemia in partial or complete second remission and partial relapse. Br J Haematol 1994;87(Suppl):205.
37. Wiernik PH, Dutcher JP, Todd M, Caliendo G, Benson L. Polyethylene glycolated interleukin-2 as maintenance therapy for acute myelogenous leukemia in second remission. Am J Hematol 1994;47(1):41-4.
38. Brune M, Mellqvist U-H, Celsing F, Wallhult K, Hellstrand K. Post-consolidation therapy with histamine and IL-2 in AML: an update [abstract 2253]. Blood 1997;90(Suppl 1)(10):506a.
39. Brune M, Hellstrand K. Remission maintenance therapy with histamine and inlerleukin-2 in acute myelogenous leukaemia. Br J Haematol 1996;92(3):620-6.
40. Hellstrand K, Asea A, Dahlgren C, Hermodsson S. Histaminergic regulation of NK cells. Role of monocyte-derived reactive oxygen metabolites. J Immunol 1994;153(11):4940-7.
41. Caligiuri MA, Zmuidzinas A, Manley TJ, Levine H, Smith KA, Ritz J. Functional consequences of interleukin-2 receptor expression on resting human lymphocytes. Identification of a novel natural killer cell subset with high affinity receptors. J Exp Med 1990;171(5):1509-26.
42. Caligiuri MA, Murray C, Soiffer RJ, Klumpp TR, Seiden M, Cochran K, et al. Extended continuous infusion low-dose recombinant interleukin-2 in advanced cancer: prolonged immunomodulation without significant toxicity. J Clin Oncol 1991;9(12):2110-9.